Study of SPARC1103 in Subjects With Spasticity

PHASE2CompletedINTERVENTIONAL
Enrollment

142

Participants

Timeline

Start Date

April 21, 2014

Primary Completion Date

April 28, 2017

Study Completion Date

April 28, 2017

Conditions
Spasticity
Interventions
DRUG

SPARC1103 low dose

once daily

DRUG

SPARC1103 high dose

once daily

DRUG

SPARC Placebo

Trial Locations (23)

Unknown

SPARC Site 4, Long Beach

SPARC Site 6, San Diego

SPARC Site 10, Aurora

SPARC Site 2, Jacksonville

SPARC Site 15, Miami

SPARC Site 7, Miami Springs

SPARC Site 5, Orlando

SPARC Site 13, Tampa

SPARC Site 11, Kansas City

SPARC Site 3, Lenexa

SPARC Site 1, Bingham Farms

SPARC Site 14, Albuquerque

SPARC Site 9, Charlotte

SPARC Site 8, Cleveland

SPARC Site 12, Richland

SPARC Site 18, Moscow

SPARC Site 17, Nizhny Novgorod

SPARC Site 20, Samara

SPARC Site 19, Smolensk

SPARC Site 16, Ufa

SPARC Site 22, Dnipro

SPARC Site 21, Ivano-Frankivsk

SPARC Site 23, Lviv

All Listed Sponsors
lead

Sun Pharma Advanced Research Company Limited

INDUSTRY

NCT02027025 - Study of SPARC1103 in Subjects With Spasticity | Biotech Hunter | Biotech Hunter